Introduction
============

Cardiac hypertrophy is considered to be a crucial risk factor for heart failure and eventually leads to systolic dysfunction, although cardiac hypertrophy is a fundamental feature of cardiac adaptation to diverse neurohumoral stimuli secondary to myocardial infarction (MI) during the early stages ([@B31]). Cardiac hypertrophy is finely regulated by a number of molecular signaling pathways.

Lysophosphatidic acid (LPA) is mainly generated by autotaxin (ATX) and is the simplest glycerophospholipid ([@B34]). As an extracellular bioactive phospholipid, LPA is widely involved in the regulation of various cellular processes, such as apoptosis, proliferation, differentiation, and migration ([@B33]; [@B50]; [@B56]; [@B52]; [@B42]), via activation of at least six known G protein-coupled receptors (GPCRs \[LPA1--LPA6\]) ([@B22]; [@B12], [@B13]; [@B54]; [@B42]). It has been reported that serum LPA levels are significantly elevated in patients with acute myocardial infarction (MI) ([@B10]). We previously reported that LPA induces cardiomyocyte hypertrophy *in vitro* ([@B49]). Moreover, LPA1 and LPA3 expression are increased in rat hearts after MI ([@B9]), implying that LPA might be involved in cardiac remodeling after a MI. The effects of LPA on cardiac function and myocardial hypertrophy during MI; however, have not been elucidated.

Autophagy is an evolutionarily conservative and physiologic process and serves to maintain normal cell function and structure by catabolizing cytoplasmic proteins and damaged organelles via lysosomes ([@B17]). Dysregulation of autophagy has been suggested to be associated with multiple disease conditions, including cardiac hypertrophy, dilated cardiomyopathy, and heart failure ([@B41]; [@B35]). A number of studies have suggested that autophagy, which is increased in the post-infarction heart ([@B26]), protects the heart against cardiac remodeling after a MI ([@B3]; [@B46]), although overactivation of autophagy might be harmful to the heart subjected to ischemia/reperfusion injury ([@B32]; [@B11]). Regulation of myocyte autophagy in cardiac remodeling, such as myocyte hypertrophy, is not fully understood. It has been reported that LPA inhibits autophagy in starvation-induced cancer cells ([@B7]) and in injured carotid artery tissues ([@B39]). Moreover, LPA is capable of regulating activation of the mammalian target of rapamycin (mTOR) pathway ([@B25]; [@B29]), which negatively mediates autophagy in various cells. Thus, we hypothesized that LPA suppresses autophagy to induce cardiomyocyte hypertrophy.

The present study investigated the effects of LPA on cardiac function and hypertrophy during MI and determined whether or not autophagy is involved in LPA-mediated cardiomyocyte hypertrophy.

Materials and Methods {#s1}
=====================

The study was approved by the Animal Care Committee of Shanxi Medical University. The animal experiments conformed to the Guide for the Care and Use of Laboratory Animals according to the Beijing Ethical Review Council on Animal Care (1996).

Materials
---------

Lysophosphatidic acid (LPA) (oleoyl C: 18:1) was obtained from Avanti Polar Lipids (Alabaster, AL, United States). 3-(4-\[4-(\[1-(2-chlorophenyl)ethoxy\]carbonylamino)-3-methyl-5-isoxazolyl\]benzylsulfanyl)propanoic acid (Kil6425) was purchased from Sigma (St. Louis, MO, United States). PI3K inhibitor LY294002, rapamycin, anti-phosphorylated mTOR (ser2448) antibody, anti-total mTOR antibody, anti-p70s6 kinase (Thr389) antibody, anti-phosphorylated p70s6 kinase, anti-4E-BP1 antibody, anti-phosphorylated 4E-BP1(Thr37/46) antibody, and anti-phosphorylated AMPKα (Thr172) antibody were obtained from Cell Signaling Technology (Beverly, MA, United States). Anti-p62/SQSTM1 (sequestosome1) polyclonal antibody and anti-beclin1 polyclonal antibody were from Proteintech Technology (Proteintech Group, Wuhan, China), and anti-LC3B polyclonal antibody and anti-GAPDH monoclonal antibody were obtained from Sigma (St. Louis, MO, United States). Lipofectamine^TM^ RNAiMAX, stealth siRNA, and siRNA negative control were purchased from life Technologies (Invitrogen, Carlsbad, CA, United States). The PowerUp^TM^ SYBR Green Master Mix assay (Applied Biosystems, Life Technologies, Foster City, CA, United States).

Animals
-------

In the present study, male Sprague-Dawley rats weighing 200 g were obtained from the Shanxi Medical University Animal Centre. All animals were housed in standard cages in a temperature-controlled (22--25°C) room on a 12-h light and 12-h dark cycle. The rats were fed with standard chow and allowed to drink water freely.

The MI rat model was established as described previously ([@B19]). In brief, 1% pentobarbital sodium (40 mg/kg body weight) was intraperitoneally injected as an anesthetic agent. The rats were ventilated with a rodent respirator and underwent thoracotomies between the fourth and fifth intercostal space. The left anterior descending coronary (LAD) artery was ligated with a 7-0 size polypropylene suture to construct the MI rat model, and occlusion was confirmed by blanching of the left ventricle anterior wall. The animals were randomly divided into the following three groups (*n* = 6--7 per group): sham operation; MI + PBS; and MI + LPA treatment. For the sham operation, rats were subjected to the same surgical procedure; however, the ligature around the LAD artery was not tied. For drug administration, rats with MI were assigned to receive intraperitoneal injections of LPA (1 mg/kg per day) or vehicle (0.1% fatty acid-free bovine serum albumin/PBS solution) 3 days after the MI. Five weeks after surgery, animal cardiac function and structure were tested by small animal echocardiography, then the animals were sacrificed by intravenous injection of 10% KCL, and the hearts were arrested in diastole and removed for further biochemical and histologic analyses.

Echocardiographic Analysis for Cardiac Structure and Function
-------------------------------------------------------------

Echocardiographic was used to assess cardiac structure and function in anesthetized rats. M-mode images were obtained to determine left ventricular dimensions, including the left ventricular internal diameter at end diastole (LVIDd), left ventricular internal diameter at end systole (LVIDs), left ventricular ejection fraction (LVEF), left ventricular posterior wall thickness at end diastole (LVPWd), left ventricular posterior wall thickness at end systole (LVPWs) and LVEF, interventricular septum at end diastole (IVSd), interventricular septum at end systole (IVSs). Fractional shortening (FS) was calculated as (LVIDd-LVIDs)/LVIDd × 100. The pooled data were analyzed for statistical significance.

Culture and Treatment of H9C2 Cardiomyoblasts
---------------------------------------------

H9C2 cardiomyoblasts were obtained from the Cell Bank at Shanghai Institute for Biological Sciences and cultured with DMEM (Gibco, CA, United States) containing 10% fetal bovine serum (Gibco, CA, United States), [D]{.smallcaps}-glucose (4.5 g/L) and penicillin/streptomycin (1000 U/ml of each) at a density of 0.1 × 10^6^ cells/35 mm in 6-well plates. The cells were then incubated at 37°C in a humidified atmosphere with 5% CO~2~ and 95% air. When H9C2 cardiomyoblasts were grown to 80% confluence, the culture medium was replaced with serum-free DMEM for 24 h. The cardiomyocytes were used for experiments after overnight serum starvation. When H9C2 cardiomyoblasts were grown to 30--50% confluence, they were used for the Fluorescent Staining experiments.

Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)
----------------------------------------------------------------------

Total RNA was extracted from cultured H9C2 cardiomyoblasts with Trizol (Invitrogen, Carlsbad, CA, United States), then quantified on a spectrophotometer. cDNA was generated from total RNA (1 μg) using reverse transcriptase and oligo (dT) 15 primer. The PowerUp^TM^ SYBR Green Master Mix assay (Applied Biosystems, Life Technologies, Foster City, CA, United States) was used to detect and quantify the mRNA levels of each gene in an Applied Biosystems 7300 (Foster City, CA, United States).

All specific sequence primers included in the present work were listed as follows: atrial natriuretic peptide (ANP): 5′-GGG TAG GAT TGA CAA GGA TTG G-3′ and 5′-CTC CAG GAG GGT ATT CAC CAC-3′; brain natriuretic peptide (BNP):5′-CTC CAG AAC AAT CCA CGA TGC-3′ and 5′-CTT CCT AAA ACA ACC TCA GCC-3′; LPA3: 5′-TGT CAA CCG CTG GCT TCT-3′ and 5′-CAG TCA TCA CCG TCT CAT TAG-3′; Beclin1: 5′-TAC TGT TCT GGG GGT TTG CG5′- and 5′-GAA CTT GAG CGC CTT TGT CC-3′; GAPDH: 5′-CAA CGA CCC CTT CAT TGA CCT-3′ and 5′-CAG TAG ACT CCA CGA CAT ACT C-3′; beta-actin: 5′-GAA CCC TAA GGC CAA CCG TGA A-3′ and 5′-TAC GTA CAT GGC TGG GGT GT -3′. In this work, GAPDH or beta-actin were used as reference genes for data normalization. The relative expression of the target gene was normalized to the reference gene using the comparative 2^-ΔΔ^*^C^*^t^ method.

Fluorescent Staining and Cell Surface Area of H9C2 Cardiomyoblasts
------------------------------------------------------------------

H9C2 cardiomyoblasts were cultured on cover slides, placed in 6-well culture plates, and treated with LPA (10 μM) alone for 24 h or pre-treated with rapamycin (a mTOR inhibitor) for 1 h before LPA treatment. H9C2 cardiomyoblasts were stained with TRITC-conjugated phalloidin solution from Sigma (St. Louis, MO, United States) for measurement of the cell surface area as previously described ([@B49]). In brief, cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 for 10 min at room temperature. After washing, cells were stained with TRITC-conjugated phalloidin at a concentration of 1 μg/ml for 1 h at 37°C. Then, DAPI staining was performed to mark the nuclei. The stained cells were imaged with a laser confocal microscope (TCS NT; Leica, Wetzlar, Germany) and assessed with ImageJ software. At least 50 H9C2 cardiomyoblasts were examined in each group.

Transfection of siRNA Into H9C2 Cardiomyoblasts
-----------------------------------------------

In the transfection experiments, H9C2 cardiomyoblasts were transfected with siRNA of Beclin1or LPA3 for 24 h, then stimulated with LPA for 4 h or 24 h. H9C2 cardiomyoblasts were transfected with small interfering RNA (siRNA) for Beclin1 or LPA3 using Lipofectamine^TM^ RNAiMAX (Invitrogen, Carlsbad, CA, United States), as previously described ([@B49]). The Beclin1 Stealth siRNA duplex target sequences were 5′-UACACCACCACCAUGAUGAAGAAGG-3′ and 5′-CCU UCU UCA UCA UGG UGG UGG UGU A-3′. The LPA3 Stealth siRNA duplex target sequences were 5′-UAC ACC ACC ACC AUG AUG AAG AAG G-3′ and 5′-CCU UCU UCA UCA UGG UGG UGG UGU A-3′. The sequence for the stealth siRNA low-GC duplex was used as a negative control. The cells were transfected with the stealth siRNA at 30 nM.

Western Blot Analysis
---------------------

Western blots were performed according to standard procedures, as previously described ([@B49]). H9C2 cardiomyoblasts or rat LV myocardial tissue samples were lysed and homogenized in a RIPA lysis buffer containing 50 mM Tris (pH = 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA 1% sodium deoxycholate, 1 mM dithiothreitol (DTT), 20 mM HEPES (pH = 7.5), 1 mM β-glycerolphosphate, 1 mM phenylmethyl sulfonylfluoride \[PMSF\] (Boster Biological Technology, Wuhan, China), and 10 μg/ml each of leupeptin, aprotinin, and pepstatin. The extract protein concentration was quantified with the BCA assay (Beyotime Biotechnology, Beijing, China). Equal amounts of protein (30--40 μg/lane) were subjected to 12% or 8% SDS-PAGE electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked in 5% skim milk for 2 h at room temperature, then the blots were incubated overnight with primary antibodies at 4°C. After washing, the blots were incubated with goat anti-rabbit IgG peroxidase-conjugated secondary antibodies for 1 h at 37°C. Western blot bands were displayed by chemiluminescence and quantified using Image LabTM analysis software. Protein bands were normalized to the control sample.

The primary antibodies were purchased from Cell Signaling Technology (Beverly, MA, United States), including anti-phosphorylated mTOR (ser2448) antibody (1:1000), anti-total mTOR antibody (1:1000), anti-p70s6 kinase (Thr389) antibody (1:1000), anti-phosphorylated p70s6 kinase (1:1000), anti-4E-BP1 antibody (1:1000), anti-phosphorylated 4E-BP1 (Thr37/46) antibody (1:1000), and anti-phosphorylated AMPKα (Thr172) antibody (1:1000). Anti-p62/SQSTM1 (sequestosome1) polyclonal antibody (1:1000) and anti-beclin1 polyclonal antibody (1:1000) were from Proteintech Technology (Proteintech Group, Wuhan, China), and anti-LC3B polyclonal antibody (1:1000) and anti-GAPDH monoclonal antibody (1:5000) were obtained from Sigma (St. Louis, MO, United States).

Hematoxylin and Eosin Staining
------------------------------

Hematoxylin and eosin staining for cardiac tissues was carried out to demonstrate the cross-sectional area of cardiac myocytes, and tissue images were examined under a light microscope. Myocyte size was determined by measurement of myocyte cross-sectional area and quantified using Image Pro Plus software. Fifty myocytes per group were measured for the data analysis.

Enzyme Linked Immunosorbent Assay (Elisa)
-----------------------------------------

Levels of troponin I in plasma from rats were quantified by the rat troponin I ELISA Kit (Elabscience Biotechnology, Wuhan, China) according to the manufacturer's instructions. Sensitivity: 9.38 pg/ml. Detection Range: 15.63--1000 pg/ml. Plasma LPA concentrations were quantified using competitive enzyme-linked immunosorbent assay (ELISA) Kit for LPA (Cloud-Clone Corp., Houston, TX, United States) following the manufacturer's instructions. Detection Range: 123.5--10000 ng/ml.

Transmission Electron Microscopy for Analysis of Autophagosomes
---------------------------------------------------------------

Transmission electron microscopy analysis was performed to detect autophagosomes in H9C2 cardiomyoblasts. Briefly, cells were collected from the cultured plates and fixed using 2.5% glutaraldehyde solution at 4°C for 2 h. Then, cells were washed and post-fixed with 1% osmic acid at 4°C for 1 h. After dehydration in methanol in a serial concentration gradient, cells were embedded in Embed-812 medium. An Ultrotome (Reichert Ultracuts; Leica) was used to make ultrathin sections of cells on uncoated copper grids. The ultrathin sections were stained with 0.2% lead citrate/1% uranyl acetate. Cell images were captured under a transmission electron microscope (JEM1230; JEOL, Japan).

Cell Counting Kit-8 Assay
-------------------------

H9C2 cardiomyoblasts were seeded in 96-well plates at a concentration of 10000 cells per well, and treated with 10 μM LPA for various lengths of time (6--48 h). Cell proliferation was assessed using Cell Counting Kit-8(CCK-8) assay (DOJINDO, Kumamoto, Kyushu, Japan).

Statistical Analysis
--------------------

Data were presented as the mean ± standard error of the mean (SEM). Differences among the groups were tested by one-way ANOVA followed by a Tukey's *post hoc* test. When there were only two means to compare, a Student's *t*-test was used. A *P* \< 0.05 was considered statistically significant. All data were analyzed using SPSS version 16.0.

Results
=======

LPA Promotes Cardiac Dysfunction and Cardiac Hypertrophy *in vivo*
------------------------------------------------------------------

Our previous study showed that LPA induces cardiomyocyte hypertrophy *in vitro* ([@B49]). To investigate the effects of LPA on cardiac function and hypertrophy induced by MI challenge, rats underwent the MI operation and were treated with LPA or PBS for 5 weeks. As presented in **Table [1](#T1){ref-type="table"}**, compared with sham-operated rats, MI rats displayed an apparent cardiac dysfunction. Importantly, LPA treatment (1 mg/kg per day) further decreased the EF and FS in rat hearts after MI, indicating that LPA aggravated cardiac dysfunction in the post-infarct heart (**Figure [1A](#F1){ref-type="fig"}**). Interestingly, we observed that LPA treatment (1 mg/kg per day) promoted cardiac hypertrophy, as indicated by hematoxylin and eosin staining of cardiac tissues, measurement of myocyte size, and natriuretic peptide B (BNP) expression (**Figures [1B--D](#F1){ref-type="fig"}**). In addition, we also found that the plasma levels of troponin I were increased in MI rats; however, there were no significant differences in troponin I levels between the LPA-treated and MI-operated groups (**Figure [1E](#F1){ref-type="fig"}**). Moreover, LPA infusion (1 mg/kg per day) caused an increase in the plasma concentrations of LPA compared with the MI-treated groups at 5 weeks post-MI (**Figure [1F](#F1){ref-type="fig"}**). There results demonstrate that LPA promotes cardiac dysfunction and hypertrophy following MI *in vivo*.

###### 

Echocardiographic parameters in each group 5 weeks after MI.

                  Sham (*n* = 6)   MI + PBS (*n* = 6)      MI + LPA (*n* = 7)
  --------------- ---------------- ----------------------- ------------------------------
  LVEF (%)             88 ± 3.25       52.33 ± 2.73^∗∗∗^         40.85 ± 2.35^∗∗∗\#^
  FS (%)          53.50 ± 4.07         23.67 ± 1.45^∗∗∗^         17.43 ± 1.15^∗∗∗\#^
  LVIDd (mm)        5.14 ± 0.59    6.63 ± 0.77             7.19 ± 0.70
  LVIDs (mm)        2.65 ± 0.45      5.11 ± 0.63^∗^            5.95 ± 0.58^∗∗^
  LVPWd (mm)        1.59 ± 0.05    2.09 ± 0.15             1.54 ± 0.27
  LVPWs (mm)        2.82 ± 0.19    2.73 ± 0.19             2.19 ± 0.30
  IVSd (mm)         1.43 ± 0.22    1.16 ± 0.17             1.03 ± 0.17
  IVSs (mm)         2.62 ± 0.22         1.61 ± 0.18^∗∗^         1.37 ± 0.20^∗∗^
  HW/BW (mg/g)      2.91 ± 0.09        3.37 ± 0.09^∗^                3.84 ± 0.13^∗∗∗\#^
  HR (beat/min)   359 ± 28         373 ± 51                383 ± 47
                                                           

LVEF, left ventricular ejection fraction; FS, fractional shortening; LVIDd, left ventricular internal diameter at end diastole; LVIDs, left ventricular internal diameter at end systole; LVPWd, left ventricular posterior wall thickness at end diastole; LVPWs, left ventricular posterior wall thickness at end systole; IVSd, interventricular septum at end diastole, IVSs interventricular septum at end systole; HW/BW: heart weight/body weight; HR: heart rate.

∗

p \< 0.05 vs. sham group,

∗∗

p \< 0.01 vs. sham group,

∗∗∗

p \< 0.001 vs. sham group.

\#

p \< 0.05 vs. MI + PBS group. Values were presented as mean ± SEM. One-way ANOVA followed by a Tukey's post hoc was used for multiple testing

.

![Lysophosphatidic acid (LPA) aggravates cardiac dysfunction and hypertrophy *in vivo*. **(A)** Representative M-mode echocardiography images of hearts in each group. **(B)** Representative hematoxylin and eosin staining of cardiac tissue section in each group. Scale bars, 50 μm. **(C)** The analysis of myocyte size. *n* = 4 rat per group, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01. **(D)** The analysis of BNP mRNA levels, *n* = 4 rat per group, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01. **(E)** The Elisa assay was used to determine the troponin I concentrations in plasma, *n* = 4 rat per group, ^∗∗^*P* \< 0.01, ^NS^*p* \> 0.05. **(F)** The Elisa assay of the LPA concentrations in plasma 5 weeks after MI, *n* = 6 rat per group, ^∗∗∗^*P* \< 0.001, ^NS^*p* \> 0.05. All data were presented as mean ± SEM. One-way ANOVA followed by a Tukey's *post hoc* was used for multiple testing.](fphys-09-01315-g001){#F1}

LPA Down-Regulates Autophagy Activity *in vitro* and *in vivo*
--------------------------------------------------------------

To determine whether or not autophagy plays a functional role in LPA-induced cardiomyocyte hypertrophy, we first explored the effect of LPA on autophagic activity. The marker protein of autophagy was determined by Western blotting in H9C2 cardiomyoblasts treated with different concentrations of LPA (0.01, 0.1, 1, 5, and 10 μM) for 4 h. As shown in **Figure [2A](#F2){ref-type="fig"}**, LPA caused a concomitant decrease in the LC3 II-to-I ratio and Beclin1 expression with a significant role at the 10 μM LPA dose. Moreover, LPA significantly increased P62/SQSTM1 expression in H9C2 cardiomyoblasts. Representative electron micrographs demonstrated decreased autophagic vacuole formation in the LPA-treated group compared with the serum-starved (SD) control group when H9C2 cardiomyoblasts were treated by 10 μM LPA for 4 h, indicating that LPA down-regulated autophagy in H9C2 cardiomyoblasts (**Figure [2B](#F2){ref-type="fig"}**). LPA also induced a hypertrophic response in H9C2 cardiomyoblasts, as assessed by sarcomere organization staining for sarcomeric F-actin, analysis of the cell surface area, and assessment of hypertrophic markers \[ANP and BNP\] (**Figures [2C--E](#F2){ref-type="fig"}**). CCK-8 assay showed that LPA promoted H9C2 cardiomyoblasts proliferation (**Figure [2F](#F2){ref-type="fig"}**). In addition, consistent with the *in vitro* experiment, LPA treatment caused down-regulation of autophagy in cardiac tissues, as shown by the decreased LC3II-to-LC3I ratio and Beclin1 expression (**Figures [3A,B](#F3){ref-type="fig"}**). These findings indicate that LPA inhibits autophagy *in vivo* and *in vitro*.

![Lysophosphatidic acid down-regulates autophagy activity *in vitro*. **(A)** Serum-starved (SD) H9C2 cardiomyoblasts were treated with different concentrations of LPA for 4 h. And then the protein levels of LC3B, Beclin1 and P62 were assessed by Western blotting. ^∗^*P* \< 0.05, ^∗∗∗^*P* \< 0.05 vs. control. **(B)** Serum-starved H9C2 cardiomyoblasts were treated with 10 μM LPA for 4 h. Representative electron micrographs demonstrating decreased autophagic vacuole formation (red arrows) in the LPA-treated group compared with the control group. Scar bar: 2 μm. **(C)** Serum-starved H9C2 cardiomyoblasts were treated with 10 μM LPA stimulation for 24 h. Sarcomere organization was stained with TRITC-conjugated phalloidin for F-actin (red). DAPI staining marked the nuclei. Scale bars, 100 μm. **(D,E)** The analysis of cell surface area and mRNA levels of ANP and BNP. *n* = 3, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 versus SD control. **(F)** H9C2 cardiomyoblasts were treated with 10 μM LPA for various lengths of time (6--48 h), cell proliferation was assessed by CCK-8 assay *n* = 3, ^∗∗^*P* \< 0.01 vs. control. All data represents mean ± SEM. Each experiment was performed thrice and shown results were representative. A one-way ANOVA followed by a *post hoc* Tukey's test was used for multiple testing. Student's t-tests were used to compare two groups of data.](fphys-09-01315-g002){#F2}

![Lysophosphatidic acid down-regulates autophagy activity *in vivo*. **(A,B)** Western blotting analysis of the protein levels of LC3B and Beclin1 in each group. *n* = 4 rat per group, values represents mean ± SEM. ^∗^*P* \< 0.05. Shown results were representative. A one-way ANOVA followed by a *post hoc* Tukey's test was used for multiple comparison.](fphys-09-01315-g003){#F3}

Autophagy Is Involved in LPA-Induced Hypertrophy in H9C2 Cardiomyoblasts
------------------------------------------------------------------------

Several studies have shown that autophagy is involved in regulation of cardiac hypertrophy induced by various stresses, such as ischemia ([@B16]) and oxidative stress ([@B15]). To determine whether or not autophagy is involved in LPA-induced cardiomyocyte hypertrophy, an autophagy activator (rapamycin) was used. We found that rapamycin increased the LC3 II-to-I ratio, decreased P62/SQSTM1 expression, and increased autophagic vacuole formation in H9C2 cardiomyoblasts incubated with LPA (**Figures [4A,B](#F4){ref-type="fig"}**). Moreover, rapamycin attenuated LPA-induced H9C2 cardiomyoblasts hypertrophy, as demonstrated by visualization of sarcomere organization, measurement of the cell surface area, and assessment of hypertrophic indicators (ANP and BNP) (**Figures [4C--F](#F4){ref-type="fig"}**). To further confirm the role of autophagy in LPA-induced cardiomyocyte hypertrophy, the autophagic protein, Beclin1, was knocked down through the transfection of Beclin1 siRNA. Knockdown of Beclin1 had no additional effect on the LPA-induced hypertrophic response in H9C2 cardiomyoblasts (**Figures [4G--I](#F4){ref-type="fig"}**). These results demonstrate that autophagy might be involved in LPA-induced H9C2 cardiomyoblast hypertrophy.

![Autophagy is involved in LPA-induced hypertrophy in H9C2 cardiomyoblasts. **(A)** H9C2 cardiomyoblasts were treated with 50 nM rapamycin (an autophagy enhancer) for 1 h, before 10 μM LPA stimulation for 4 h. The protein levels of LC3B and p62 were detected by Western Blotting. *n* = 3, ^∗^*P* \< 0.05. **(B)** Representative electron micrographs of autophagic vacuole formation in H9C2 cardiomyoblasts (red arrows). Scale bars, 2 μm. **(C)** H9C2 cardiomyoblasts were treated with 50 nM rapamycin for 1 h, before 10 μM LPA stimulation for 24 h. Sarcomere organization determined by TRITC-conjugated phalloidin for F-actin (red). DAPI staining marked the nuclei. Scale bars, 100 μm. The assessment of cell surface area and mRNA levels of ANP and BNP **(D--F)**. *n* = 3, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01. H9C2 cardiomyoblasts were transfected with siRNA of Beclin1 for 24 h, and then exposed to 10 μM LPA for 24 h. The mRNA levels of ANP and BNP **(G,H)**. *n* = 3, ^∗^*P* \< 0.05, ^ns^*p* \> 0.05. H9C2 cardiomyoblasts were transfected with siRNA of Beclin1 for 24 h. Then the mRNA levels of Beclin1 were analyzed by qRT-PCR **(I)**. *n* = 3, ^∗∗^*P* \< 0.01. All data represents mean ± SEM. Each experiment was performed thrice and shown results were representative ones. A one-way ANOVA followed by a *post hoc* Tukey's test was used for multiple comparison. Student's *t*-tests were used to compare two groups of data.](fphys-09-01315-g004){#F4}

AKT/mTOR Pathway Is Required for LPA-Induced Autophagy Inhibition
-----------------------------------------------------------------

Abundant evidence has shown that the AMP activated protein kinase (AMPK)/mTOR signaling pathway is essential in mediating autophagy ([@B32]; [@B3], [@B4]; [@B23]). To determine whether or not AMPK/mTOR signaling is involved in LPA-regulated autophagy in cardiomyocytes, Western blotting analysis was performed to assess phosphorylated AMPK and mTOR in H9C2 cardiomyoblasts exposed to 10 μM LPA at the indicated times. There was no significant decrease in the phosphorylation of AMPKa determined by Western blotting in H9C2 cardiomyoblasts after administration of LPA (**Figure [5A](#F5){ref-type="fig"}**). Importantly, we found that LPA induced an increase in the phosphorylation of mTOR and its downstream targets (p70S6K and 4E-BP1) (**Figure [5B](#F5){ref-type="fig"}**), and these effects were abrogated by rapamycin, a mTOR inhibitor (**Figure [5C](#F5){ref-type="fig"}**). In addition, AKT is an upstream regulatory molecule of the mTOR signaling pathway. Our previous study identified that the PI3K inhibitor, LY294002, attenuates LPA-induced cardiomyocyte hypertrophy *in vitro* ([@B49]). In this work, we observed that the PI3K inhibitor, LY294002, prevented the LPA--mediated effects on the mTOR pathway and autophagy (**Figures [5D,E](#F5){ref-type="fig"}**). Together, these data indicate that the AKT/mTOR pathway is involved in mediating LPA-induced autophagy inhibition in H9C2 cardiomyoblasts.

![Lysophosphatidic acid down-regulates autophagy through the AKT/mTOR pathway. **(A,B)** Western blotting analysis of the phosphorylation of AMPKα (Thr172), mTOR (Ser2448), P70S6 kinase (Thr389), and 4E-BP1 (Thr37/46) in H9C2 cardiomyoblasts treated with 10 μM LPA for the indicated time. ^∗^*P* \< 0.05 vs. control, ^ns^*P* \> 0.05. **(C)** H9C2 cardiomyoblasts were treated with 50 nM rapamycin for 1 h, before 10 μM LPA stimulation for 15 min. Then the phosphorylation of mTOR and P70S6 kinase were analyzed by Western blotting. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01. **(D)** H9C2 cardiomyoblasts were treated with 6.25 μM LY294002 for 1 h, and then exposed to 10 μM LPA for 15 min. The phosphorylation of mTOR and p70S6 kinase were analyzed by Western blotting. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01. **(E)** H9C2 cardiomyoblasts were treated with 6.25 μM LY294002 for 1 h, before exposure to 10 μM LPA for 4 h. Then the protein levels of LC3B were determined by Western blotting. ^∗^*P* \< 0.05. All data represents mean ± SEM. Each experiment was performed thrice and shown results were representative. A one-way ANOVA followed by a *post hoc* Tukey's test was used for multiple comparison.](fphys-09-01315-g005){#F5}

LPA Down-Regulates Autophagy Through LPA3
-----------------------------------------

Our previous study showed that LPA induced a hypertrophic response through LPA3 in cardiomyocytes ([@B49]). To determine whether or not LPA3 is involved in down-regulated autophagy in cardiomyocytes by LPA, the non-selective LPA1/3 antagonist, Ki16425, was used. We found that Ki16425 attenuated the down-regulation of autophagy caused by LPA, as indicated by LC3II and p62 expression (**Figures [6A,B](#F6){ref-type="fig"}**). Moreover, LPA-induced phosphorylation of mTOR and 4E-BP1 were also alleviated by Ki16425, as shown by the Western blotting of mTOR and 4E-BP1 (**Figures [6C,D](#F6){ref-type="fig"}**). Moreover, knock-down of LPA3 through siRNA transfection also reduced LPA-mediated effects on autophagy and H9C2 cardiomyoblast hypertrophy (**Figures [6E--I](#F6){ref-type="fig"}**). Knock-down of LPA3 suppressed LPA3 mRNA levels in H9C2 cardiomyoblasts (**Figure [6J](#F6){ref-type="fig"}**). These results demonstrate that LPA inhibits autophagy through activation of the LPA3 receptor.

![Knockdown of LPA3 attenuates LPA-mediated autophagy inhibition. **(A,B)** Serum-starved H9C2 cardiomyoblasts were treated with 10 μM Ki16425 for 1 h, before exposure to 10 μM LPA for 4 h. Then the protein levels of LC3B and P62 were tested by Western blotting. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01. **(C,D)** The phosphorylation of mTOR and 4E-BP1 analyzed by Western blotting in H9C2 cardiomyoblasts treated with 10 μM Ki16425 for 1 h, before 10 μM LPA stimulation for 15 min. ^∗^*P* \< 0.05. **(E,F)** H9C2 cardiomyoblasts were transfected with siRNA of LPA3 for 24 h, and then exposed to 10 μM LPA for 4 h. The protein levels of LC3B and p62 were detected by Western blotting. ^∗^*P* \< 0.05. **(G)** H9C2 cardiomyoblasts were transfected with siRNA of LPA3 for 24 h, before exposure to 10 μM LPA for 24 h. The mRNA levels of BNP were analyzed by qRT-PCR. *n* = 3, ^∗∗^*P* \< 0.01. **(H)** Sarcomere organization determined by TRITC-conjugated phalloidin for F-actin (red). DAPI staining marked the nuclei. Scale bars, 100 μm. **(I)** The assessment of cell surface area. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01. **(J)** Serum-starved H9C2 cardiomyoblasts were transfected with siRNA of LPA3 for 24 h, The mRNA levels of LPA3 were tested by qRT-PCR. *n* = 3, ^∗∗^*P* \< 0.01. All data represents mean ± SEM. Each experiment was performed thrice and shown results were representative. A one-way ANOVA followed by a *post hoc* Tukey's test was used for multiple comparison. Student's *t*-tests were used to compare two groups of data.](fphys-09-01315-g006){#F6}

Discussion
==========

The major findings of this study were as follows: (i) LPA aggravated cardiac dysfunction and promoted cardiac hypertrophy following MI; (ii) LPA down-regulated autophagy *in vivo* and *in vitro*; (iii) autophagy was involved in LPA-induced H9C2 cardiomyoblast hypertrophy; and (iv) LPA down-regulated autophagy through activation of the LPA3 receptor and mTOR signaling pathway. This study revealed the role of exogenous LPA in the heart after a MI. In addition, this data suggested that autophagy is involved in the LPA-induced hypertrophic effect.

LPA, as a phospholipid signaling molecule, which is produced from circulating lysophosphatidylcholine (LPC) by ATX, is involved in multiple cardiovascular diseases ([@B40]; [@B8]; [@B21]; [@B36]; [@B39]). It has been reported that LPA is present in abundance in the serum of patients with an acute myocardial infarction (AMI) ([@B10]), and LPA1 and LPA3 receptor protein levels are increased in the ischemic heart that develops cardiac remodeling, implying that LPA plays a role in cardiac remodeling after a MI. The current study showed that exogenous LPA worsens systolic function in terms of decreased EF and FS, suggesting that LPA is involved in regulation of cardiac function after a MI. Previous studies have shown that LPA induces cardiomyocyte hypertrophy in primary neonatal rat cardiac myocytes ([@B24]; [@B9]; [@B49]). In the current study, we showed that LPA promotes cardiac hypertrophy *in vivo*, suggesting that LPA might cause cardiac dysfunction by inducing cardiac remodeling. In addition, LPA can mediate diverse actions on cardiac muscle, including modulation of left ventricular systolic and diastolic pressures ([@B47]), myocardial contractility ([@B14]) and electrophysiological instability ([@B45]). LPA also enhances ventricular arrhythmias in rabbit heart 2 weeks after a MI ([@B55]). Therefore, this report did not exclude the possibility that LPA contributes to cardiac dysfunction by other mechanisms, such as regulation of ventricular arrhythmias ([@B55]). LPA infusion increased LPA concentrations in plasma at 5 weeks post-MI. It may be associated with the inflammatory response induced by LPA. Because LPA stimulated inflammatory cytokines whereas the production of inflammatory cytokines in damaged tissue serve as a signal for increased ATX expression and LPA production to heal the wound ([@B2]; [@B1]). If inflammation is unresolved, inflammatory cytokines produced by LPA may cause further ATX expression which in turn increased LPA formation, thereby leading to more cytokine production in a vicious cycle ([@B1]). Thus, exogenous LPA can change circulating LPA levels and strengthen LPA signaling in damaged and inflamed tissue, although LPA has an extremely fast turnover. Interestingly, too little LPA might have similar effects as too much LPA. For instance, effects of LPA on angiogenesis are the same in ATX knockout mice and transgenic mice overexpressing ATX ([@B44]; [@B43];[@B53]).

Lysophosphatidic acid has been reported to protect cardiomyocytes against apoptosis ([@B27]), and we recently showed that LPA protects immature cardiomyocytes from I/R injury ([@B8]); however, no significant difference in troponin I levels between the LPA-treated and MI-operated groups was demonstrated. The discrepancy may be attributed to the different experimental models. Lipid phosphate phosphatase 3 (LPP3), is a major enzyme that dephosphorylates LPA. Cardiac-specific inactivation of LPP3 displays cardiac hypertrophy and myocardial dysfunction in mice, indicating that the LPA/LPP3-signaling play an important role in normal function of cardiomyocytes ([@B6]). These data indirectly support the findings in the current study. In addition, LPA3 knockout mice exhibited reduced cardiac hypertrophy compared to wild-type mice post-MI ([@B5]), indicating that LPA/LPA3 signaling is required for cardiac hypertrophy after MI. In terms of regulation of cardiac hypertrophy, this report supports the mention in the present study.

Accumulating evidence demonstrated that activation of autophagy is increased in ischemic hearts and serves as a protective mechanism against adverse cardiac remodeling in the post-infarction heart ([@B26]; [@B30]; [@B46]). In agreement with previous studies, we also observed that autophagic protein markers were increased in the post-infarction heart. Previous evidence has shown that LPA inhibits autophagy in starvation-induced cancer cells ([@B7]). Recently, LPA has been reported to promote neointimal hyperplasia after vascular injury by regulating autophagy ([@B39]). In the present study, the results showed that LPA suppresses activation of autophagy *in vivo* and *in vitro*. Moreover, *in vitro* experiments showed that activation of autophagy through rapamycin not only counteracted autophagy suppression, but also attenuated the induction of H9C2 cardiomyoblast hypertrophy by LPA. These results demonstrated that autophagy suppression is involved in LPA-induced cardiomyocyte hypertrophy.

AMP activated protein kinase, as a central energy sensor that regulates cellular metabolism to maintain energy homeostasis, induces the activity of autophagy ([@B32]; [@B23]). Conversely, the AKT/mTOR signaling pathway, which could be activated by LPA ([@B25]; [@B29]), is thought to be an important negative regulator of autophagy ([@B57]; [@B48]). In the current study, LPA had no significant effect on the phosphorylation of AMPKα; however, LPA promoted the phosphorylation of mTOR and its downstream targets; Furthermore, we indicate that LPA regulated autophagy via the AKT/mTOR pathway in H9C2 cardiomyoblasts because LPA-mediated autophagy inhibition was significantly prevented by mTOR and PI3K inhibitors. It has been reported that mTOR activity prevents the interaction between AMPK and the autophagy-initiating kinase Ulk1 by phosphorylating Ulk1 Ser 757 ([@B28]), thereby leading to autophagy inhibition. We found that LPA increased phosphorylated Ulk1 Ser 757 (data not shown). Thus, LPA may disturb the interaction between AMPK and Ulk1 through mTOR activation, eventually leading to autophagy suppression. Further studies will be required in the future. In addition, we found that knockdown of LPA3 blocked LPA-regulated autophagy suppression, indicating that LPA3 is involved in LPA-induced autophagy inhibition. Our data provide evidence that LPA might cause autophagy inhibition through LPA3 and the mTOR pathway. There may be some other mediators responsible for the cardiac hypertrophy promotion of LPA. For example, as protein kinase D1 (PKD-1) activator, LPA promotes angiogenesis and microvascular remodeling ([@B51]; [@B38]; [@B37]; [@B18]), which are closely associated with cardiac hypertrophy. LPA stimulates PKD-1 signaling in our model (data not shown) whereas PKD-1 signaling is required for pathological cardiac remodeling ([@B20]). Thus, it would be interesting to know whether LPA-mediated vascular remodeling and PKD-1 signaling is responsible for cardiac hypertrophy.

There were several limitations in this study. First, the regulatory mechanism of autophagy by which LPA caused cardiac dysfunction and remodeling was not thoroughly investigated *in vivo*. Second, we did not employ specific LPA3 receptor antagonist or LPA3 knockout mice to investigate the pinpoint mechanism of how LPA influence hearts following MI *in vivo*, so further *in vivo* experiments remained necessary. In addition, some experiments should be performed in primary cells. Further investigation is required in the future.

In summary, this study demonstrated that LPA contributes to cardiac dysfunction and hypertrophy *in vivo*. *In vitro* experiments suggested that LPA induces H9C2 cardiomyoblast hypertrophy by down-regulating autophagy, which is dependent on the LPA3/AKT/mTOR pathway. These findings provided the first evidence to identify a novel role of LPA in the post-infarction heart and reveal a link between LPA and autophagy in cardiomyocyte hypertrophy. Therefore, targeting LPA signaling might be a therapeutic strategy for the ischemic heart and cardiac hypertrophy.
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